Novel sinomenine derivative 1032 improves immune suppression in experimental autoimmune encephalomyelitis

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 1093-1098

  Yan, Ling Chen ^a   Bi, En Guang ^a   Lou, Yang Tong ^c   Wu, Xiao Dong ^a   Liu, Zhi Duo ^a   Zhou, Jia ^a   Wang, Yuan ^a   Ma, Zhao ^a   Lin, Guo Mei ^a   Sun, Shu Hui ^d   Bian, Chao ^a   Chen, Ai Zhong ^a   Yao, Zhu Jun ^c   Sun, Bing ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Chemical modification; EAE; NF B; Sinomenine (SIN); Th17 cells

Indexed keywords

I KAPPA B ALPHA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 6; MORPHINAN DERIVATIVE; SINOMENINE DERIVATIVE 1032; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL;

ANIMALS; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; I-KAPPA B PROTEINS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MORPHINANS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

SINOMENIUM ACUTUM;

EID: 72949115494     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.028     Document Type: Article

References (32)

1. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2 (2001) 762-764
2. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
3. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
4. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
5. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., Lee J., de Sauvage F.J., and Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7 (2006) 929-936
6. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
7. Managan P.R., et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441 (2006) 231-234
8. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
9. Sutton C., Brereton C., Keogh B., Mills K.H.G., and Lavelle C. A crucial role for interleukin(IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203 (2006) 1685-1691
10. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., Oukka M., and Kuchroo V.k. Il-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
11. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., Levy D.E., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8 (2007) 967-974
12. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., and Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343 (2000) 898-904
13. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer III F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
14. Rizvi S.A., and Agius M.A. Current approved options for treating patients with multiple sclerosis. Neurology 63 (2004) S8-S14
15. Wang Z., Qiu J., Guo T.B., Liu A., Wang Y., Li Y., and Zhang J.Z. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J. Immunol. 179 (2007) 5958-5965
16. Newman D.J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J. Med. Chem. 51 (2008) 2589-2599
17. Newman D.J., Cragg G.M., and Snader K.M. Natural Products as Sources of New Drugs over the Period 1981-2002. J. Nat. Prod. 66 7 (2003) 1022-1037
18. Hajduk, and Greer P.J. A recent review on fragment-based strategy. J. Nat. Rev. Drug Discov. 6 (2007) 211-219
19. Wang Y., Fang Y., Huang W., Zhou X., Wang M., Zhong B., and Peng D. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol. 98 (2005) 37-43
20. He X., Wang J., Guo Z., Liu Q., Chen T., Wang X., and Cao X. Requirement for ERK activation in sinomenine-induced apoptosis of macrophages. Immunol. Lett. 98 (2005) 91-96
21. Kok T.W., Yue P.Y., Mak N.K., Fan T.P., Liu L., and Wong R.N. The anti-angiogenic effect of sinomenine. Angiogenesis 8 (2005) 3-12
22. Yamasaki H. Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med. Okayama 30 (1976) 1-20
23. Liu L., Buchner E., Beitze D., Schmidt-Weber C.B., Kaever V., Emmrich F., and Kinne R.W. Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Int. J. Immunopharmacol. 18 (1996) 529-543
24. Patents: Yao, Z.-J.; Zhou, H.-B. CN1687065-A, CN1298718-C (ZL 2005 1 0024478.9).
25. Yao, Z.-J.; Zhou, H.-B. CN1687070-A, CN1298720-C (ZL 2005 1 0024479.3).
26. De Rosa V., Procaccini C., La Cava A., Chieffi P., Nicoletti G.F., Fontana S., Zappacosta S., and Matarese G. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J. Clin. Invest. 116 (2006) 447-455
27. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., and Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176 (1992) 1693
28. Wang A.L., Li Z., Yuan M., Yu A.C., Zhu X., and Tso M.O. Sinomenine inhibits activation of rat retinal microglia induced by advanced glycation end products. Int. Immunopharmacol. 7 (2007) 1552-1558
29. Huang J., Lin Z., Luo M., Lu C., Kim M.H., Yu B., and Gu J. Sinomenine suppresses TNF-alpha-induced VCAM-1 expression in human umbilical vein endothelial cells. J. Ethnopharmacol. 114 (2007) 180-185
30. Kriehuber E., Bauer W., Charbonnier A.S., Winter D., Amatschek S., Tamandl D., Schweifer N., Stingl G., and Maurer D. Balance between NF-κB and JNK/AP-1 activity controls dendritic cell life and death. Blood 106 (2005) 175-183
31. Onishi H., Kuroki H., Matsumoto K., Baba E., Sasaki N., Kuga H., Tanaka M., Katano M., and Morisaki T. Monocyte-derived dendritic cells that capture through IL-12/TNF-α/NF-κB autocrine loop. Cancer Immunol. Immunother. 53 (2004) 1093-1100
32. Rescigno M., Martino M., Sutherland C.L., Gold M.R., and Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188 (1998) 2175-2180